205 related articles for article (PubMed ID: 37014050)
21. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
22. Microbial exopolysaccharides-β-glucans-as promising postbiotic candidates in vaccine adjuvants.
Abbasi A; Rahbar Saadat T; Rahbar Saadat Y
Int J Biol Macromol; 2022 Dec; 223(Pt A):346-361. PubMed ID: 36347372
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in self-adjuvanting glycoconjugate vaccines.
Manabe Y; Chang TC; Fukase K
Drug Discov Today Technol; 2020 Dec; 37():61-71. PubMed ID: 34895656
[TBL] [Abstract][Full Text] [Related]
24. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.
Obeid J; Hu Y; Slingluff CL
Semin Oncol; 2015 Aug; 42(4):549-61. PubMed ID: 26320060
[TBL] [Abstract][Full Text] [Related]
25. Iron nanoparticles as novel vaccine adjuvants.
Behzadi M; Vakili B; Ebrahiminezhad A; Nezafat N
Eur J Pharm Sci; 2021 Apr; 159():105718. PubMed ID: 33465476
[TBL] [Abstract][Full Text] [Related]
26. Vaccine Adjuvants: Selection Criteria, Mechanism of Action Associated with Immune Responses and Future Directions.
Habib A; Anjum KM; Iqbal R; Jaffar G; Ashraf Z; Khalid MS; Taj MU; Zainab SW; Umair M; Zohaib M; Khalid T
Iran J Immunol; 2023 Mar; 20(1):1-15. PubMed ID: 36917475
[TBL] [Abstract][Full Text] [Related]
27. Computer-Aided Discovery of Potent Broad-Spectrum Vaccine Adjuvants.
Ma J; Wang S; Zhao C; Yan X; Ren Q; Dong Z; Qiu J; Liu Y; Shan Q; Xu M; Yan B; Liu S
Angew Chem Int Ed Engl; 2023 Apr; 62(18):e202301059. PubMed ID: 36815280
[TBL] [Abstract][Full Text] [Related]
28. In vitro naphthylquinoxaline thymidine conjugate and UVA treated cancer cells are effective therapeutic vaccines for tumors in vivo with CpG as the adjuvant.
Yang R; Zhou S; Zhou Q
J Adv Res; 2022 Jan; 35():259-266. PubMed ID: 35003803
[TBL] [Abstract][Full Text] [Related]
29. Chemical Strategies to Boost Cancer Vaccines.
Li WH; Li YM
Chem Rev; 2020 Oct; 120(20):11420-11478. PubMed ID: 32914967
[TBL] [Abstract][Full Text] [Related]
30. Challenges facing adjuvants for cancer immunotherapy.
Mesa C; Fernández LE
Immunol Cell Biol; 2004 Dec; 82(6):644-50. PubMed ID: 15550123
[TBL] [Abstract][Full Text] [Related]
31. Formulation of IMXQB: Nanoparticles Based on Quillaja brasiliensis Saponins to be Used as Vaccine Adjuvants.
Rivera-Patron M; Cibulski SP; Miraballes I; Silveira F
Methods Mol Biol; 2022; 2469():183-191. PubMed ID: 35508839
[TBL] [Abstract][Full Text] [Related]
32. Utilization of gut environment-mediated control system of host immunity in the development of vaccine adjuvants.
Liu Z; Hosomi K; Kunisawa J
Vaccine; 2022 Aug; 40(36):5399-5403. PubMed ID: 35918205
[TBL] [Abstract][Full Text] [Related]
33. Engineering the immune system with particles, step-by-step.
De Geest BG
Mol Immunol; 2018 Jun; 98():25-27. PubMed ID: 29526503
[TBL] [Abstract][Full Text] [Related]
34. Self-adjuvanting cancer nanovaccines.
Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
[TBL] [Abstract][Full Text] [Related]
35. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
[No Abstract] [Full Text] [Related]
36. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
Vermaelen K
Front Immunol; 2019; 10():8. PubMed ID: 30723469
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in adjuvant discovery for peptide-based subunit vaccines.
Azmi F; Ahmad Fuaad AA; Skwarczynski M; Toth I
Hum Vaccin Immunother; 2014; 10(3):778-96. PubMed ID: 24300669
[TBL] [Abstract][Full Text] [Related]
38. Vaccine adjuvants to engage the cross-presentation pathway.
Lee W; Suresh M
Front Immunol; 2022; 13():940047. PubMed ID: 35979365
[TBL] [Abstract][Full Text] [Related]
39. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
40. Bioorthogonal-Activated In Situ Vaccine Mediated by a COF-Based Catalytic Platform for Potent Cancer Immunotherapy.
Sun M; Liu Z; Wu L; Yang J; Ren J; Qu X
J Am Chem Soc; 2023 Mar; 145(9):5330-5341. PubMed ID: 36815731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
